Mylan prevails in Sanofi's Lantus SoloSTAR patent battle
UK-incorporated generics drugmaker Mylan (Nasdaq: MYL) has moved a step nearer to marketing its copy version of Lantus (insulin glargine) in the USA, as the District Court of New Jersey yesterday found the device patent claims (US Patent No 9,526,844) asserted by French pharma major Sanofi (Euronext: SAN) against Mylan's insulin glargine product not infringed and invalid for lack of written description.
Mylan’s shares closed up 4.87% at $14.08 on Tuesday following the announcement.
Separately, as previously announced, Sanofi's formulation patents (US Patent No 7,476,652 and US Patent No 7,713,930) were previously affirmed to be invalid by the Federal Circuit. The '844 and '652 patents were the only patents being asserted by Sanofi against Mylan's insulin glargine product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze